Recent transition of medical cost and relapse rate of multiple sclerosis in Japan based on analysis of a health insurance claims database

doi:10.21203/rs.2.9293/v1

Download PDF

Research article

Recent transition of medical cost and relapse rate of multiple sclerosis in Japan based on analysis of a health insurance claims database

https://doi.org/10.21203/rs.2.9293/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 16 Dec, 2019

Read the published version in BMC Neurology →

You are reading this older preprint version

Read the latest preprint version →

Background

In this study, we aimed to understand the trends in total and itemized medical expenses, especially of disease-modifying therapy (DMT), for multiple sclerosis (MS) in Japan through an analysis of health insurance claims data.

Methods

We analyzed a database containing health insurance claims data from hospitals that have adopted the Diagnosis Procedure Combination/Per-Diem Payment System in Japan. According to an algorithm based on diagnosis codes, data for all patients diagnosed with MS from April 2008 to July 2016 were extracted. Medical costs, rate of each medical treatment, and rate of relapses were analyzed by calendar-year. Medical costs in the month of relapse were compared with average medical costs per month of all MS patients by a cross-sectional analysis.

Results

4,374 MS patients were identified in the database. Total medical cost per patient per month (PPPM) increased from \87,640 (US$787.7 or €723.0 as of May 2017) to \102,846 (US$924.4 or €848.4) during the study period. This increment was mainly attributed to the growth in cost of outpatient DMT prescriptions, which increased from \23,039 (US$207.1 or €190.1) to \51,351 (US$461.5 or €423.6). In contrast, the rate of hospitalizations and relapses PPPM decreased during the study period (from 0.053 to 0.030, and 0.032 to 0.019, respectively). Medical costs in the month of relapse (\424,661, US$3816.8 or €3503.1) were 3.57 times higher than the average monthly costs for all MS patients (\119,021, US$1069.8 or €981.8), with the majority comprising hospitalization cost.

Conclusion

Concomitant with the increased usage of DMT, the total medical cost for treating MS is increasing in Japan. However, rates of relapse and hospitalization have shown a decreasing trend. There is currently a lack of evidence for direct causality between DMT and reduction of relapse rates. However, even if DMT cannot be directly shown to be the cause of lower relapse rates and fewer hospitalizations among MS patients, a better quality of life for MS patients and a reduction in hospital costs have been achieved concomitantly with the increasing prevalence of DMT.

Internal Medicine Specialties

multiple sclerosis

disease-modifying therapy

claims database

health economics

relapse rate

real-world data

Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system that often affects young adults and causes progressive physical and cognitive disability [1, 2] . MS is one of the most common neurodegenerative diseases in the United States and Europe and has affected approximately 2.3 million people worldwide (in 2013) [3]. In recent years, disease-modifying therapy (DMT) has been commonly used to prevent relapse in a certain type of MS—relapsing–remitting multiple sclerosis [4, 5]. After the launch of interferon (IFN) β, the first DMT drug, in 1993, there has been rapid growth in the number of DMT drugs on the market [6]. In the United States, 12 DMT drugs are currently available. The cost of DMT has almost doubled from 2008 to 2012 in the United States, with a 5 to 7 times higher rate of annual increase compared to that of other prescription drugs [7]. The average cost of DMT per patient per month (PPPM) in 2013 was approximately $2400, comprising more than 60% of the total medical cost for MS [8]. Therefore, the cost of DMT imposes significant economic burden on healthcare systems in the United States [9].

In Asian countries, including Japan, the prevalence of MS is lower than in the United States and Europe. Therefore, MS has not received much attention from an economic perspective in Asian countries. However, the prevalence of MS has been reported to be steadily increasing in Japan and other Asian counties [10, 11]. Moreover, DMT has gained wider acceptance in recent years, leading to a steep growth in the economic impact of MS in these countries. In our previous study based on a Japanese claims database, the average medical cost PPPM for MS was \93,542, which was approximately 3.7-fold higher than that for the general population in Japan [12]. Furthermore, we found that DMT comprised the largest component of medical costs for patients younger than 50 years. This result demonstrated the high cost associated with MS in Japan, most of which is attributable to DMT. Given that both MS prevalence and use of DMT are increasing in Japan and other Asian countries, it is important to obtain recent information pertaining to trends in the medical costs of MS, particularly with a focus on DMT.

In this study, we conducted a calendar-year analysis to reveal the latest trends of medical cost for MS in Japan, with a special focus on DMT. We used the same type of claims database as that used in our previous study [12] and conducted a long-term analysis from 2008 to 2016 to evaluate the dynamic transition of total and itemized medical costs, which was not covered in the previous study [12]. Furthermore, we assessed the transition of the relapse rate and changes in the rates of each medical treatment and compared medical costs during the month of a relapse with the average monthly medical costs to quantify the cost of medical treatment associated with relapse. Considering the rapid growth of the DMT market, our study aims to provide useful information for healthcare providers and policymakers in choosing treatments for MS, and to conduct appropriate economic evaluations of DMT.

Data sources

Health insurance claims data for April 2008 to July 2016 provided by Medical Data Vision (MDV) were used in this study. The database collects data from acute care hospitals adopting the Diagnosis Procedure Combination/Per-Diem Payment System (DPC/PDPS), also known as DPC hospitals. DPC hospitals comprised approximately 21% of all hospitals and accounted for nearly 55% of total hospital beds in Japan as of May 2015. The MDV database covered approximately 11.7 million patients treated in 208 DPC hospitals, accounting for approximately 13% of all DPC hospitals in Japan as of September 2015. As DPC hospitals are usually large hospitals, these data may be biased without the inclusion of data from small-scale hospitals and clinics.

The database contains diagnosis codes according to International Classification of Disease tenth revision (ICD-10), Japanese procedure codes, and prescriptions containing generic drug names submitted for health insurance claims.

Patient identification

Patients were determined to have MS according to the ICD-10 diagnosis code G35: multiple sclerosis. We identified patients with MS using the following algorithm (Table 1) [12]:

(1) Patients with at least one claim with a definitive MS diagnosis were extracted.

(2) Patients who had at least one claim with neuromyelitis optica (NMO; 3410003 by Japanese disease name codes) were excluded.

(3) Patients who met any of the following criteria were included in the study population:

* Those who had at least one hospitalization claim with a definitive MS diagnosis.

* Those who had at least one outpatient claim with a definitive MS diagnosis and had at least one DMT claim.

* Those who had at least one outpatient claim with a definitive MS diagnosis and a record of diagnostic start date before the observation period. The diagnostic start date is defined as the day of the outpatient claim with the first diagnosis of the disease.

* Those who had at least three outpatient claims with a definitive MS diagnosis.

DMT drugs

Drugs prescribed to prevent relapse of MS were defined as DMT. Eight DMT drugs were analyzed in this study, including IFN-β (including both 1a and 1b), natalizumab, cyclophosphamide hydrate, azathioprine, tacrolimus hydrate, fingolimod, glatiramer acetate, and prednisolone. Prednisolone is used not only as a DMT drug but also to treat relapse symptoms. Therefore, prednisolone used in relapse treatment, as described in subsequent sections, was excluded from the analysis. The duration of treatment for injectable DMTs was calculated based on the days supplied per prescription and the number of prescriptions, because the number of days for injectable drug prescriptions was not in the database. The days supplied per prescription for IFN-β-1a, IFN-β-1b, natalizumab, cyclophosphamide hydrate, and glatiramer acetate were defined as 7, 2, 28, 28, and 1, respectively.

Statistical analysis

We conducted calendar-year analysis to examine medical costs, rate of medical treatments, and rates of relapse from 2008 to 2016. The total medical cost was subdivided into inpatient and outpatient costs, and was further itemized into categories, such as medical procedure, imaging, laboratory test, DMT, prescription drugs for relapse treatment, and prescription drugs other than relapse treatment costs. Drugs used for relapse treatment were defined as injectable forms of prednisolone sodium succinate, dexamethasone phosphate ester sodium, and methylpredonisolone sodium succinate. Since data for 2016 only covers claims from January to July, we made the following adjustment: an adjustment coefficient was calculated by dividing the total medical cost in 2015 by the medical cost from January to July in 2015. This coefficient was multiplied times the medical cost from January to July for 2016 to calculate the adjusted annual cost for 2016. For calculating medical costs and rates of each medical treatment and relapse PPPM, we defined the observation period for each patient as the length of time from the first claim date with definitive MS diagnosis (either inpatient or outpatient), which is defined as the index date, to the last claim data in the dataset. The date of relapse was defined as the date of the first injection of a series of drugs used in relapse treatment at least 30 days after the index date. If multiple claims of relapse treatment were found within 30 days, only the first claim was counted as a relapse. If the interval between two relapse treatments exceeded 30 days, they were counted as separate relapses. DMT-treated patients were defined who at least once prescribed DMT in each calendar year. For these patients, medication possession ratio of DMT was calculated by dividing the number of days for which patients were supplied with DMT by the total number of days in observation period in each calendar year. Statistical analysis was performed using SAS version 9.2 (SAS institute, Cary, NC, USA).

Exchange rate

Following exchange rates as of May 2017 were used to convert Japanese yen to US dollar and euro described in the text; US$1 = \111.26, €1 = \121.22.

Patient background extracted from the database

We extracted 4,374 patients with MS who met our study inclusion criteria (Table 1). Figure 1A shows the monthly patient count by gender and the female ratio of MS patients in the study population. The number of MS patients has abruptly increased in recent years because of the expansion of the database. The proportion of females was nearly constant between 65% and 67% after August 2008. The average age of patients stabilized between 48–52 years after April 2010 (Figure 1B).

We counted the number of MS patients who had at least one claim for a DMT prescription in each calendar year (Table 2). The percentage of DMT-treated patients was 33% in 2008 and rapidly increased after 2012 to reach 46% in 2014; thereafter, it remained nearly stable.

Medical costs by year

Table 3 shows total and itemized medical costs PPPM for each calendar year from 2008 to 2016. In 2008, total medical cost was \87,640 (US$787.7 or €723.0), and it slightly decreased to \77,539 (US$696.9 or €639.6) in 2012; however, it markedly increased thereafter to \102,846 (US$924.4 or €848.4) in 2016. During the study period from 2008 to 2016, the total outpatient cost increased from \44,059 (US$396.0 or €363.4) to \71,854 (US$645.8 or €592.7), whereas inpatient cost decreased from \43,581 (US$391.7 or €359.5) to \30,993 (US$278.6 or €255.7). Focusing our analysis on itemized expenses, we observed that the outpatient DMT cost rapidly increased from 2013 onward; it nearly doubled during the study period, from \23,039 (US$207.1 or €190.1) in 2008 to \51,351 (US$461.5 or €423.6) in 2016. Cost of outpatient imaging, laboratory tests, and prescription drugs other than DMT or relapse treatment increased marginally but not as markedly as outpatient DMT costs. Figure 2 summarizes the annual costs of inpatient (without DMT), DMT, and other medical costs. The percentage of DMT in total medical cost was 27% in 2008 but increased to 51% in 2016 (P < 0.001). The ratio of inpatient cost decreased from 49% to 29% (P < 0.001), and other medical costs did not significantly change (P = 0.64).

Medical treatment and relapse rates by year

We next analyzed the rate (number PPPM) of each medical treatment and relapse for each calendar year from 2008 to 2016 (Table 4). The relapse rate decreased from 0.032 to 0.019 PPPM during the study period. Concomitantly, the rates of hospitalization and relapse treatment decreased from 0.053 to 0.030 PPPM and from 0.44 to 0.15 PPPM, respectively. With regard to DMT drugs, the prescription rate did not considerably change (from 0.39 to 0.35 PPPM), but days supplied per prescription increased from 18.07 to 28.64. Concomitantly, percentage of duration for which DMT-treated patients were supplied with DMT (defined as medication possession ratio) increased from 63% to 73% of the observation period (Figure 3). Other utilization rates, including outpatient treatment, imaging, laboratory tests, and prescription drugs other than relapse treatment or DMT tended to slightly decrease; however, the changes were not as drastic as the decrease in relapse or hospitalization rates (Table 4).

Medical costs for patients in the month of relapse

We compared the medical costs PPPM in the month of relapse with the average medical costs PPPM for all MS patients (Table 5). In the month of relapse, total medical cost PPPM was \424,661 (US$3816.8 or €3503.1), which was 3.57 times higher than the cost for all MS patients (\119,021, US$1069.8 or €981.8). Approximately 80% (\335,556, US$3016.0 or €2768.0) of medical costs in the relapse month was inpatient cost, whereas inpatient cost comprised only 30% (\34,877, US$313.5 or €287.7) of total MS-related costs for all MS patients. With regard to outpatient costs, expenditure on imaging and pharmacotherapy in relapse months were higher than in the average month (\6,869, US$61.7 or €56.7 vs. \1,941, US$17.4 or €16.0; \2,692, US$24.2 or €22.2 vs. \75, US$0.67 or €0.62, respectively); however, the cost of DMT was lower than the average cost per month for all MS patients (\51,874, US$466.2 or €427.9 vs. \60,323, US$542.1 or €497.6).

In this study, we analyzed real-world patient claims data and showed the latest trends of medical costs, relapse rates, and rates of each category of medical treatment for MS in Japan. The MDV database is one of the largest claims databases in Japan, and it enabled efficient analysis of the nationwide trends in the treatment of MS. We extracted data for 4,374 MS patients from the dataset, and this is a much larger study population than that included in our previous study [12]. In 2014, the study population MS patients cover approximately 15% of the total number of MS patients in Japan [13]. The total medical cost for MS increased rapidly from 2012 to 2016, mainly due to increases in DMT cost. Concomitantly, the relapse rate as well as rate of hospitalization almost constantly decreased during the study period. Although our data did not reveal a direct causality between DMT and reduction of the relapse rate, it is demonstrated that disease progression in MS has decelerated, with longer time in remission correlated with the prevalence of DMT use.

Increase of medical costs for MS in Japan

Our previous analysis showed that the medical cost PPPM for MS patients from October 2013 to September 2014 was \93,542 (US$840.8 or €771.6), of which \45,284 (US$407.0 or €373.6) was outpatient DMT cost [12]. This study updated these data and showed the latest trends for categories of medical costs.

The total medical cost for MS did not dramatically change from 2008 to 2012, but increased rapidly thereafter. The total increment in cost during the study period was approximately \15,200 (US$137 or €125) PPPM, corresponding to 17% of medical cost in 2008 (Table 3). Further, outpatient DMT cost sharply increased after 2012 and was more than twice as high by 2016. Since other medical costs did not show such drastic changes, the increment in total medical cost was mostly attributed to the growth in outpatient DMT cost. In addition, the percentage of MS patients treated with DMT rapidly increased after 2012 (35% in 2012 to 44% in 2016; Table 2), suggesting that DMT is more commonly prescribed to MS patients, including those in early disease stages due to increased recognition of its benefit [14]. In addition, the first oral DMT drug, fingolimod, was launched in November 2011 in Japan. Fingolimod now sees widespread use, comprising nearly one third of the total DMT prescription in Japan [15]. The rapid increase in DMT cost from 2012 may, at least partially, be attributable to the propagation of fingolimod.

The ratio of DMT cost to total MS-related cost increased from 27% to 51% during the study period (Figure 2). In the United States, DMT cost has substantially increased over the last decade and currently constitutes more than 60% of the total MS-related cost [7, 8]. In the United States, more than 67% of all MS-affected patients are estimated to be treated with DMT [8]. The prevalence of DMT among MS patients is likely to increase further in Japan. In addition, the number of DMT drugs is expected to increase in Japan; for example, dimethyl fumarate, a new oral DMT, was approved in December 2016. Therefore, the market size as well as economic impact of DMT is likely to grow further in Japan to approach the situation in the United States.

Relapse and medical treatment rates

In Japan, the cost of DMT has markedly increased since 2012. As the unit price of each DMT did not significantly change during the study period, either or both the supply of total DMT or/and the ratio of DMT with higher price have expanded. Although the number of DMT prescriptions did not substantially change during the study period (Table 4), days supplied per prescription increased by nearly 11 days, leading to the increase of total DMT supplies (Table 4). This partly accounts for the increase in DMT cost. In Japan, newly launched drugs cannot be prescribed for more than 14 days at a time. For fingolimod, this limitation was lifted in November 2012, and long-term prescription was permitted. In addition, natalizumab, which is normally administered every 4 weeks, was launched in June 2014. As prices of fingolimod and natalizumab are higher than prices for other conventional DMT drugs, such as IFN-β, increased prescription of these new drugs may also account for the increase of DMT cost without any change in the prescription frequency.

Concurrent with the increase of DMT cost and usage, the rate of relapses per month declined by approximately 40% (from 0.032 to 0.019) during the study period (Table 4, Figure 3). Together with the decreased relapse rate, rates of hospitalization and relapse treatment also decreased. Although our data do not show any direct causality, the observed relationship suggests that DMT drugs reduced the incidence of relapse, which led to decreased hospitalization and relapse treatment. However, we cannot exclude the possibility that other factors, such as early diagnosis of MS, may have contributed to the reduction of the relapse rate. The DMT cost as well as supply increased sharply after 2012 (Table 2, Table 4), whereas the relapse rate constantly decreased from 2009 to 2016 (Figure 3). This suggests that DMT alone may not have affected the relapse rate, and that other factors, such as rate of patients with mild MS symptoms, are also likely to be involved.

The reduction of inpatient cost (Table 3 and Figure 2) is explained by the fall in relapse rate and consequent reduction of the number (or days) of hospitalizations. Despite significant decrease in inpatient cost, the increase in DMT cost exceeded this decrement, leading to a substantial increase in total MS-related medical cost.

Interestingly, we found that adherence of MS patients to DMT increased after 2011 (Figure 3), probably due to the launch and propagation of fingolimod and natalizumab that were more convenient for patients. This may have contributed to success in treatment, leading to longer remission and less hospitalization of MS patients. Although these new drugs are costly, their utilities are recognized, and increased usage of these drugs may have inflated the recent growth of DMT cost.

Medical costs for patients with relapsing MS

Medical costs PPPM in the relapse month were 3.6-fold higher than the average medical cost PPPM for all MS patients (Table 5). This difference was mostly attributable to the difference of inpatient cost. The inpatient cost in the relapse month was approximately 10 times higher than that of the average monthly medical cost for MS. As relapse is often associated with functional impairment of patients, many patients require hospitalization for administration of acute relapse treatment. Therefore, reduction of the relapse rate not only contributes to improved quality of life for the patient but also helps reduce hospitalization costs [16].

Limitations

Since the database included data from DPC hospitals, treatment outside the hospital were not captured. The size of the database has expanded rapidly due to the increase in DPC hospitals included in the MDV database. Therefore, the patient background may not be consistent in each calendar year; for example, the average age of the patient varied greatly before 2010 (Figure 1B). As patient data were anonymized before receipt, the history of each patient cannot be tracked either before the first visit to the hospital or after changing hospitals. For calculating costs or numbers PPPM, we defined the observation period as the length of time from the first to the last claim data for each patient and used this as the denominator. As this observation period is shorter than the insurance coverage period for each patient, the calculated value PPPM may have been an overestimate. Since only the relapses treated at the hospital that were in the database could be captured, the frequency and costs for relapses might have been underestimated.

Conclusions

Based on real-world data analysis, we revealed that DMT cost has grown rapidly in recent years, leading to an increase of total medical cost for MS in Japan. However, the number of relapses and hospitalizations are constantly decreasing. Although DMT is expensive, it may help reduce the relapse rate, thereby enabling lower costs due to relapsed patients, such as hospitalization and relapse treatment expenses. It is necessary to evaluate the cost of DMT in the context of total medical treatment costs, particularly considering the quality of life of MS patients [17] In Japan, an increasing number of MS patients are treated with DMT because its beneficial aspects have been increasingly recognized among both physicians and patients. The DMT market is expected to further expand in Japan as well as in other Asian countries, with a number of new DMT drugs awaiting clinical launch. Given this, our data may provide useful information for healthcare providers and policymakers in these countries to enable better decision making with regard to MS treatment. In addition, the maturing process of DMT market in Japan revealed in this study from the viewpoint of both economics and utility may help other countries to evaluate and predict their own DMT market in the future.

MS: multiple sclerosis, IFN: interferon, PPPM: per patient per month, DPC/PDPS: Diagnosis Procedure Combination/Per Diem Payment System, MDV: Medical Data Vision, ICD-10: International Classification of Disease 10th edition, NMO: neuromyelitis optica

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

The data that support the findings of this study are available from Medical Data Vision Co., Ltd. but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Medical Data Vision Co., Ltd.

Competing interests

IK has received funding for research, travel and/or speaker honoraria from Novartis Pharma, Biogen, Bayer Yakuhin Limited, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Comapany Limited, Japan Blood Products Organization and Astellas Pharma, and is a scientific advisory board member for Biogen and Takeda Pharmaceutical Company Limited. MO has received funding for travel from Takeda Pharmaceutical Company Limited. SO, MS and, HO, MY, and SH are employees of Takeda Pharmaceutical Company Limited. KI and YN areis an employees of Milliman. MY, and SH were employed by Takeda Pharmaceutical Company Limited., and YN was employed by Milliman, during the execution of this research. MO has received funding for travel from Takeda Pharmaceutical Company Limited. The authors declare that they have no competing interests.

Funding

This work was financially supported by Takeda Pharmaceutical Company Limited and a Health and Labour Science Research Grant on Rare and Intractable Diseases (Evidence-based Early Diagnosis and Treatment Strategies for Neuroimmunological Diseases) from the Ministry of Health, Labour and Welfare of Japan. Financial support for writing and editorial assistance was provided by Takeda Pharmaceutical Company Limited.

Authors’ contributions

IK conceived and designed the study, and interpreted the data. SO designed the study and interpreted the data. MS interpreted the data and revised the article. HO conceived and designed the study, and interpreted the data. YN conducted the analysis. KI conducted the analysis and interpreted the data. MY coordinated the study and interpreted the data. SH designed the study and interpreted the data. MO conceived and designed the study, and interpreted the data. All authors have read and approved the manuscript.

Acknowledgements

The authors thank Ms. Jill Van Den Bos at Milliman for proofreading the manuscript, and Dr. Rumiko Kamo-Mizuguchi at Milliman for writing and editorial support.

1. Frohman EM, Racke MK, Raine CS. Multiple sclerosis – the plaque and its pathogenesis. N Engl J Med. 2006;354:942-55.

2. Kawachi I, Lassmann H. Neurodegeneration in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2017;88:137-45.

3. Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, et al. Atlas of multiple sclerosis 2013: A growing global problem with widespread inequity. Neurology. 2014;83:1022-4.

4. Finkelsztejn A. Multiple sclerosis: overview of disease-modifying agents. Perspect Medicin Chem. 2014;6:65-72.

5. Torkildsen Ø, Myhr KM, Bø L. Disease-modifying treatments for multiple sclerosis–a review of approved medications. Eur J Neurol. 2016;23:18-27.

6. Bin Sawad A, Seoane-Vazquez E, Rodriguez-Monguio R, Turkistani F. Price analysis of multiple sclerosis disease-modifying therapies marketed in the United States. Curr Med Res Opin. 2016;32:1783-8.

7. Hartung DM, Bourdette DN, Ahmed SM, Whitham RH. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail? Neurology. 2015;84:2185-92.

8. Milliman, Inc., NY. Multiple Sclerosis: New perspectives on the patient journey. Milliman Client Report. April 2016 http://us.milliman.com/uploadedFiles/insight/2016/multiple-sclerosis-new-perspectives.pdf

9. Owens GM. Economic burden of multiple sclerosis and the role of managed care organizations in multiple sclerosis management. Am J Manag Care. 2016;22:S151-8.

10. Osoegawa M, Kira J, Fukuzawa T, Fujihara K, Kikuchi S, Matsui M, et al. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years.

Mult Scler. 2009;15:159-73.

11. Eskandarieh S, Heydarpour P, Minagar A, Pourmand S, Sahraian MA. Multiple sclerosis epidemiology in east Asia, south east Asia and south Asia: A systematic review. Neuroepidemiology. 2016;46:209-21.

12. Ogino M, Kawachi I, Otake K, Ohta H, Otsuka Y, Iwasaki K, et al. Current treatment status and medical cost for multiple sclerosis based on analysis of a Japanese claims database. Clin Exp Neuroimmunol. 2016;7:158-67.

13. Japan Intractable Disease Information Center. Number of patients who were certified to receive subsidies for the medical treatment of multiple sclerosis (In Japanese). Available from URL: http://www.nanbyou.or.jp/entry/1356

14. Freedman MS, Comi G, Stefano ND, Barkhof F, Polman CH, Uitdehaag BMJ, et al. Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. Mult Scler Relat Disord. 2014;3:147-55.

15. Ogino M, Okamoto S, Ohta H, Sakamoto M, Nakamura Y, Iwasaki K, et al. Prevalence, treatments and medical cost of multiple sclerosis in Japan based on analysis of a health insurance claims database. Clin Exp Neuroimmunol. 2017;8:318-26.

16. Tan H, Yu J, Tabby D, Devries A, Singer J. Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort study. Mult Scler. 2010;16:956-63.

17. Noyes K, Bajorska A, Chappel A, Schwid SR, Mehta LR, Weinstock-Guttman B, et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis. A population-based study. Neurology. 2011;77:355-63.

Due to technical limitations the tables could not be inserted here and can be found in the Supplemental files.

supplement1.pdf

Download PDF

Journal Publication

published 16 Dec, 2019

Read the published version in BMC Neurology →

Editorial decision: Major revision
29 Jul, 2019
Review #2 received at journal
24 Jul, 2019
Reviewer #2 agreed at journal
10 Jul, 2019
Review #1 received at journal
15 May, 2019
Reviewer #1 agreed at journal
24 Apr, 2019
Submission checks completed at journal
19 Apr, 2019
Reviewers invited by journal
19 Apr, 2019
Editor invited by journal
27 Mar, 2019
Editor assigned by journal
27 Mar, 2019
First submitted to journal
20 Mar, 2019

You are reading this older preprint version

Read the latest preprint version →

Recent transition of medical cost and relapse rate of multiple sclerosis in Japan based on analysis of a health insurance claims database

Status:

Journal Publication

Version 1

Abstract

Figures

Background

Methods

Results

Discussion

List of abbreviations

Declarations

References

Tables

Supplementary Files

Status:

Journal Publication

Version 1